Xuanzhu Biopharmaceutical Co., Ltd.( “Xuanzhu Biopharm”) has completed a Series B financing of RMB610.5 million on December 31, 2021. This round of financing was led by Sunshine Life Insurance Corporation Limited and joined by Efung Capital, Zhongji Investment Co., Ltd., TJ Capital, SDIC Taikang Trust Co., Ltd., Hai Chuang Fund of Funds, BOC Capital, Jinjiang Xuanhong Equity Investment, Shaanxi Financial Holding Group, Hainan Wanxin Private Equity Fund Management, DNV Capital, Huayi Capital and other renowned investment institutions. WinX Capital was the exclusive financial advisor for this financing round.
This is a new round financing following the Series A financing of RMB963 million, a strategic investment led by SDIC China Merchants in August 2020. The participation of heavy-weighted strategic investors in both rounds fully demonstrates Xuanzhu Biopharm’s unceasing innovation capabilities and the forward-looking layout of Sihuan Pharmaceutical which the capital market has recognized. The financing will further accelerate Xuanzhu Biopharm’s vision of “an innovative biopharmaceutical company rooted in China with a global perspective”.
As the first spin-off innovative drug subsidiary of Sihuan Pharmaceutical, Xuanzhu Biopharm will continue to increase investment in the development and global deployment of innovative drug R&D pipelines and persist in enhancing its independent innovation capabilities.
Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Group, said: “We are delighted to witness the recognition of the strategic plan of Sihuan Pharmaceutical Group and the prospects of Xuanzhu Biopharm by Sunshine Insurance and many well-known institutions. Sihuan Pharmaceutical adheres to two-wheel drive strategy of independent innovation and research and incubation to cultivate high growth new businesses. We conform to the industry’s development trend, persist on innovation and leadership, and continue to increase the investment in R&D. These initiatives are instituted to realize the innovative transformation and development of Sihuan Pharmaceutical Group and to create a new paradigm of internationalized pharmaceutical technology companies. Sihuan Pharmaceutical has been deeply involved in the pharmaceutical industry for 20 years. The accumulated wealth of experience and industry resources will undoubtedly propel Xuanzhu Biopharm’s transformation from “Biotech” to “Biopharm”. As Xuanzhu Biopharm is gradually integrating R&D, industrialization and commercialization capabilities, Sihuan Pharmaceutical’s support will help Xuanzhu Biopharm land on the capital market in the near future.
Ms. Xu Yanjun, Chairman of Xuanzhu Biopharm, said: “We express our sincere gratitude to the professional investment institutions in this round of financing. Their participation signifies their recognition of and full confidence in the team and R&D capabilities of Xuanzhu Biopharm. As always, Xuanzhu Biopharm will continue to build a novel drug R&D system based on independent and original development. At the same time, we will gradually expand the comprehensive strength encompassing overseas collaboration, industrialization and commercialization, and create a novel, innovative pipeline and portfolio that is differentiated and sustainable. The new investment we gained will help Xuanzhu Biopharm to accelerate its vision of an innovative biopharmaceutical company rooted in China with a global perspective.”